Spots Global Cancer Trial Database for leukemia, lymphoid
Every month we try and update this database with for leukemia, lymphoid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT | NCT06075238 | Leukemia, Lymph... | blinatumomab | 16 Years - 65 Years | Sichuan University | |
| Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | NCT01471782 | Acute Lymphobla... | Blinatumomab | - 17 Years | Amgen Research (Munich) GmbH | |
| Immune Reconstitution After Allo-HSCT and Blinatumomab | NCT06075212 | Leukemia, Lymph... | blinatumomab | 16 Years - 65 Years | Sichuan University | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies | NCT00569179 | Leukemia, Myelo... Leukemia, Lymph... Myelodysplastic... Leukemia, Myelo... | CliniMACS CD34 ... | 18 Years - 65 Years | Indiana University | |
| Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | NCT01466179 | Acute Lymphobla... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG | NCT02916979 | Leukemia, Lymph... Leukemia, Myelo... Myelodysplastic... Myelofibrosis Lymphoma, Malig... Multiple Myelom... Waldenstrom Mac... | Fludarabine Busulfan Rabbit ATG Methotrexate | 18 Years - 75 Years | Dartmouth-Hitchcock Medical Center | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | NCT06001385 | Acute Lymphobla... Acute Myeloid L... Acute Leukemia Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Lymphoma Chronic Myelomo... Pro-Lymphocytic... Myelofibrosis | Busulfan Fludarabine PBSC Hematopoie... Post-Transplant... Mesna Tacrolimus Mycophenolate M... Patient Reporte... Melphalan Total-body irra... Cyclophosphamid... | 18 Years - | Center for International Blood and Marrow Transplant Research | |
| ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) | NCT02670564 | Acute Lymphobla... | Pharmacogenomic... Busulfan plasma... | - 18 Years | Swiss Pediatric Oncology Group | |
| Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia | NCT03573700 | Acute Lymphobla... Acute Lymphobla... | Cyclophosphamid... Fludarabine Mesna CliniMACS CD19- specific ... | - 21 Years | St. Jude Children's Research Hospital | |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | NCT03833180 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac... | Zilovertamab ve... | 18 Years - | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors | NCT00701844 | Leukemia Acute Leukemia Acute Lymphocyt... Multiple Myelom... Hematological C... Psychological D... | Writing A (Expe... Writing B (Expe... Writing C (Cont... Writing D (Cont... | 18 Years - | University of North Carolina, Chapel Hill | |
| Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors | NCT00701844 | Leukemia Acute Leukemia Acute Lymphocyt... Multiple Myelom... Hematological C... Psychological D... | Writing A (Expe... Writing B (Expe... Writing C (Cont... Writing D (Cont... | 18 Years - | University of North Carolina, Chapel Hill | |
| Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL | NCT06111625 | Leukemia, Lymph... | blinatumomab | 16 Years - 65 Years | Sichuan University | |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | NCT03833180 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac... | Zilovertamab ve... | 18 Years - | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma | NCT00849654 | B-Cell Lymphoma B-Cell Leukemia | PCI-32765 | 18 Years - | Pharmacyclics LLC. | |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide | NCT04904588 | Acute Lymphobla... Acute Myelogeno... Mixed Phenotype... Acute Leukemia Myelodysplastic... Chronic Myeloge... Chronic Lymphoc... Lymphoma | Busulfan Busulfan Fludarabine Total-body irra... Cyclophosphamid... Melphalan PBSC Hematopoie... Bone Marrow Hem... Post-transplant... Mesna Tacrolimus Mycophenolate M... Patient-Reporte... | 1 Year - | Center for International Blood and Marrow Transplant Research | |
| A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies | NCT00569179 | Leukemia, Myelo... Leukemia, Lymph... Myelodysplastic... Leukemia, Myelo... | CliniMACS CD34 ... | 18 Years - 65 Years | Indiana University | |
| Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) | NCT01292135 | B-cell Chronic ... Small Lymphocyt... | PCI-32765 | 18 Years - | Pharmacyclics LLC. | |
| Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia | NCT01116193 | Leukemia, Lymph... Precursor B-Cel... | Lenalidomide pl... | 18 Years - | Institut de Cancérologie de la Loire | |
| Safety of PCI-32765 in Chronic Lymphocytic Leukemia | NCT01105247 | B-cell Chronic ... Small Lymphocyt... | PCI-32765 | 18 Years - | Pharmacyclics LLC. | |
| Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) | NCT01292135 | B-cell Chronic ... Small Lymphocyt... | PCI-32765 | 18 Years - | Pharmacyclics LLC. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
